DOCSLIB.ORG

Product Catalog

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Product Catalog Personalized Molecular Medicine ® 2018 Standardized solutions for the diagnosis, PRODUCT stratification, monitoring & study of oncology CATALOG Industry Pioneers We pride ourselves on staying at the forefront of new technologies. We oer a full range of standardized CE-marked in vitro diagnostic products for detection of hematological malignancies, as well as RUO assays, analyte specific reagents, and nucleic acid controls. Letter to Our Colleagues Our LymphoTrack® Dx and LymphoTrack® Assays for use on both the Illumina® MiSeq® and Thermo Fisher Scientific® Ion PGM™ instruments can be used to identify clonal lymphocyte populations, track minimal residual disease, and evaluate the status of somatic hypermutation Dear Colleagues: using our comprehensive, easy-to-use bioinformatics software. I am pleased to introduce our 2018 Product Catalog and I would like to take this opportunity to share some 2017 developments and Our CE-IVD gold-standard B- and T-cell PCR-based gel and capillary testing reagents, developed under ISO 13485 design control, are future plans at Invivoscribe. standardized, molecular hematopathology products that reduce discordance between laboratories and increase sensitivity and specificity. In April of 2017 we received FDA approval of our PMA for the LeukoStrat® CDx FLT3 Mutation Assay, a companion diagnostic that aids in the selection of patients with AML for whom midostaurin treatment is being considered. We were pleased to see successful culmination of the work we did for our partner, Novartis, and confirmation of the capabilities of our excellent team. In addition, Global Reach we have now validated and released a CE-marked IVD version of this assay for use outside North America (page 62), and we are The Invivoscribe portfolio of cGMP products are currently being used by more than 700 clinical and research laboratories across 105 working towards FDA approval of a distributable version of this assay, so that we can oer it as a kitted product to our customers countries worldwide. here in the US. In 2017 we also released the LymphoTrack® TRB Assay. We now provide a comprehensive menu of LymphoTrack® Clonality Assays along with comprehensive interpretative LymphoTrack® software for the MiSeq® next-generation sequencing (NGS) platform (page 20). We will release our TRB Assay for Thermo Fisher® NGS platforms later this year. LymphoTrack® assays are used to identify and track clonal rearrangements within the antigen receptor loci (IGH, IGK, TRG, TRB). The 24 ID format allows customers to significantly reduce costs, as you can run any combination of the 7 assays (up to 154 samples and 14 controls) simultaneously, while the accompanying bioinformatics software automatically sorts and interprets the data for each targeted region and sequence ID. Our team has enjoyed significant satisfaction in seeing our Research Use Only (RUO) assays being used in research and clinical trials in the US, and our CE-marked IVD versions of the assays being used by leading cancer centers abroad. These assays assist in the diagnosis and tracking of a wide variety of hematologic malignancies, and they are also used to evaluate somatic hypermutation (SHM) in chronic lymphocytic leukemia (CLL). In fact, a group at Oxford has already published a paper in Leukemia, describing use of Invivoscribe, Inc. our IGHV SHM Assay and our LymphoTrack® bioinformatics software in order to update prognostic stratification of patients with CLL. San Diego, CA, USA These clonality assays will be submitted for review via the US FDA’s 510(k) process. Additionally, our LymphoTrack® assays are also being used in concert with accompanying minimal residual disease (MRD) bioinformatics software, for the study of MRD in a wide LabPMM LLC range of hematologic malignancies, including multiple myeloma and acute lymphoblastic leukemia. San Diego, CA, USA Our number of international clinical trials have expanded for one of our other pharmaceutical partners, Astellas, and we developed, validated and have started monitoring clinical trial subjects using our internationally standardized and CLIA/CAP-listed FLT3-ITD MRD assay that may be up to two logs more sensitive than other FLT3 assays. These MRD assays and bioinformatics software are being used as a tool to support clinical validation endpoints in drug development studies for a number of pharmaceutical partners. We expect a paper describing the use of this assay to be published soon. In our continuing eorts towards achieving international harmonization of molecular diagnostic testing, we are developing and will soon release a series of LymphoQuant™ MRD controls that can be used as internal spike-in controls with all of our MRD assays to help leading cancer research centers quantify residual disease. Further, our LymphoTrack® assays identify many CAR-T and engineered T cell constructs, so in a research or clinical trial setting they can be used throughout treatment to simultaneously identify and track both the subject’s immune response and levels of immuno-therapy constructs. To accommodate our rapid growth, Invivoscribe has moved into a brand-new, custom-designed facility in San Diego, more than doubling our previous company headquarter’s space. We increased sta£ng in our San Diego (USA) and Martinsried (Germany) ISO 15189 accredited clinical laboratories, allowing us to provide clinical testing services 6 days a week. We set up a clinical laboratory in Japan, where we have started clinical testing and enrollment of subjects for clinical trials. In addition, we also opened an o£ce in Shanghai (Invivoscribe Diagnostic Technology Co. Ltd.), to support clinical trials in China. We have also expanded our NGS portfolio, developing and launching several NGS-based panels, including MRD testing for a number of hematologic biomarkers. Our MyAML®, MyMRD™, and MyHeme® gene panels, combined with our custom bioinformatics pipeline, MyInformatics™, are oered as RUO only and/or as CLIA/CAP-listed tests through our clinical laboratories in the USA, Invivoscribe, SARL Europe and Asia. La Ciotat, FR Our continued growth and progress would not be possible without your constant feedback and support. We look forward to LabPMM GmbH continuing our interaction with the research and clinical communities so we can oer you the best molecular products for decades to Munich, DE come. We wish you, your colleagues, and your families a joyful, productive, and successful 2018. Sincerely Yours, Invivoscribe Diagnostic Technologies (Shanghai) Co. Ltd. Shanghai, CN Jerey E. Miller, PhD LabPMM GK Founder, Chief Scientific & Chief Executive O£cer, and Chairman Tokyo, JP Table of Contents Introduction T-Cell Receptor Gamma Gene Rearrangement Assays 90 TCRG Gene Clonality Assays 92 Letter to Our Colleagues 1 TCRD Gene Clonality Assays 94 BCL1/JH Translocation Assay 96 Background BCL2/JH t(14;18) Translocation Assay 98 Introduction 4 BCL2/JH Translocation Assay 100 Test Algorithm for Suspect Lymphoproliferations 5 BCR/ABL t(9;22) Translocation Assays 102 PML/RARa t(15;17) Translocation Assays 104 Next-Generation Sequencing (NGS) IGH Somatic Hypermutation Assays v2.0 106 FLT3 Mutation Assays 108 LymphoTrack® Dx Assays 6 LymphoTrack Dx IGHV Leader Somatic Hypermutation Assay 8 Analyte Specific Reagents LymphoTrack Dx IGH FR1/2/3 Assays 10 LymphoTrack Dx IGK Assays 14 Analyte Specific Reagents 110 LymphoTrack Dx TRG Assays 16 LymphoTrack Dx TRB Assays 18 Controls LymphoTrack Dx Bioinformatics Software 20 Overview 112 DNA Controls 114 LymphoTrack® Assays Research Use Only (RUO) 22 RNA Controls 118 LymphoTrack IGHV Leader Somatic Hypermutation Assay 24 Control Panels 122 LymphoTrack IGH FR1/FR2/FR3 Assays 26 Master Mix Controls 124 LymphoTrack IGK Assays 30 Reagents 125 LymphoTrack TRG Assays 32 Enzymes 125 LymphoTrack TRB Assays 34 LymphoTrack Bioinformatics Software 36 Custom Products LymphoTrack Bioinformatics Software 38 Custom Products 126 Gel and Capillary Services: NGS Cancer Panels 128 TM IdentiClone Assays 40 MyAML® 130 IGH + IGK B-Cell Clonality Assays 42 MyHEME® 132 IGH Gene Clonality Assays 44 MyMRD™ 134 IGK Gene Clonality Assays 46 IGL Gene Clonality Assays 48 Reference 136 TCRB + TCRG T-Cell Clonality Assays 50 Clonality Testing Workflow Methods 137 TCRB Gene Clonality Assays 52 Illumina® MiSeq® Workflow Summary 138 T-Cell Receptor Gamma Gene Rearrangement Assay 2.0 54 Thermo Fisher Scientific® Ion PGM™ Workflow Summary 139 TCRG Gene Clonality Assays 56 Next-Generation Sequencing Menu 140 TCRD Gene Clonality Assays 58 Gel and Capillary Electrophoresis Menu 141 BCL1/JH Translocation Assay 60 Hematologic Malignancy Research and Testing Guide 142 BCL2/JH Translocation Assay 62 Common Technical Support Questions 143 Recent Poster Abstracts 146 LeukoStrat® Assays 64 FLT3 Mutation Assay - Gel 66 Product List FLT3 Mutation Assay 2.0 - ABI Fluorescence 68 Product List by Catalog Number 148 CDx FLT3 Mutation Assay 70 Index Research Use Only (RUO) Assays 72 Alphabetical Index 152 IGH + IGK B-Cell Clonality Assays 74 IGH Gene Rearrangement Assays 76 IGH Gene Clonality Assays 78 IGK Gene Clonality Assays 80 IGL Gene Clonality Assays 82 TCRB + TCRG T-Cell Clonality Assays 84 TCRB Gene Clonality Assays 86 T-Cell Receptor Gamma Gene Rearrangement Assay 2.0 88 2 Background Test Algorithm for Suspect Lymphoproliferations Developed in concert with the EuroClonality/BIOMED-2 group for PCR-based clonality assessment of suspected B- and T-cell lymphoproliferative disorders. If a definitive diagnosis is not possible following: Morphology Immunohistochemistry Flow Cytometry PCR & NGS-Based
Load more

Recommended publications
  • Podocyte Specific Knockdown of Klf15 in Podocin-Cre Klf15flox/Flox Mice Was Confirmed
    SUPPLEMENTARY FIGURE LEGENDS Supplementary Figure 1: Podocyte specific knockdown of Klf15 in Podocin-Cre Klf15flox/flox mice was confirmed. (A) Primary glomerular epithelial cells (PGECs) were isolated from 12-week old Podocin-Cre Klf15flox/flox and Podocin-Cre Klf15+/+ mice and cultured at 37°C for 1 week. Real-time PCR was performed for Nephrin, Podocin, Synaptopodin, and Wt1 mRNA expression (n=6, ***p<0.001, Mann-Whitney test). (B) Real- time PCR was performed for Klf15 mRNA expression (n=6, *p<0.05, Mann-Whitney test). (C) Protein was also extracted and western blot analysis for Klf15 was performed. The representative blot of three independent experiments is shown in the top panel. The bottom panel shows the quantification of Klf15 by densitometry (n=3, *p<0.05, Mann-Whitney test). (D) Immunofluorescence staining for Klf15 and Wt1 was performed in 12-week old Podocin-Cre Klf15flox/flox and Podocin-Cre Klf15+/+ mice. Representative images from four mice in each group are shown in the left panel (X 20). Arrows show colocalization of Klf15 and Wt1. Arrowheads show a lack of colocalization. Asterisk demonstrates nonspecific Wt1 staining. “R” represents autofluorescence from RBCs. In the right panel, a total of 30 glomeruli were selected in each mouse and quantification of Klf15 staining in the podocytes was determined by the ratio of Klf15+ and Wt1+ cells to Wt1+ cells (n=6 mice, **p<0.01, unpaired t test). Supplementary Figure 2: LPS treated Podocin-Cre Klf15flox/flox mice exhibit a lack of recovery in proteinaceous casts and tubular dilatation after DEX administration.
    [Show full text]
  • Table 2. Significant
    Table 2. Significant (Q < 0.05 and |d | > 0.5) transcripts from the meta-analysis Gene Chr Mb Gene Name Affy ProbeSet cDNA_IDs d HAP/LAP d HAP/LAP d d IS Average d Ztest P values Q-value Symbol ID (study #5) 1 2 STS B2m 2 122 beta-2 microglobulin 1452428_a_at AI848245 1.75334941 4 3.2 4 3.2316485 1.07398E-09 5.69E-08 Man2b1 8 84.4 mannosidase 2, alpha B1 1416340_a_at H4049B01 3.75722111 3.87309653 2.1 1.6 2.84852656 5.32443E-07 1.58E-05 1110032A03Rik 9 50.9 RIKEN cDNA 1110032A03 gene 1417211_a_at H4035E05 4 1.66015788 4 1.7 2.82772795 2.94266E-05 0.000527 NA 9 48.5 --- 1456111_at 3.43701477 1.85785922 4 2 2.8237185 9.97969E-08 3.48E-06 Scn4b 9 45.3 Sodium channel, type IV, beta 1434008_at AI844796 3.79536664 1.63774235 3.3 2.3 2.75319499 1.48057E-08 6.21E-07 polypeptide Gadd45gip1 8 84.1 RIKEN cDNA 2310040G17 gene 1417619_at 4 3.38875643 1.4 2 2.69163229 8.84279E-06 0.0001904 BC056474 15 12.1 Mus musculus cDNA clone 1424117_at H3030A06 3.95752801 2.42838452 1.9 2.2 2.62132809 1.3344E-08 5.66E-07 MGC:67360 IMAGE:6823629, complete cds NA 4 153 guanine nucleotide binding protein, 1454696_at -3.46081884 -4 -1.3 -1.6 -2.6026947 8.58458E-05 0.0012617 beta 1 Gnb1 4 153 guanine nucleotide binding protein, 1417432_a_at H3094D02 -3.13334396 -4 -1.6 -1.7 -2.5946297 1.04542E-05 0.0002202 beta 1 Gadd45gip1 8 84.1 RAD23a homolog (S.
    [Show full text]
  • Chemical Agent and Antibodies B-Raf Inhibitor RAF265
    Supplemental Materials and Methods: Chemical agent and antibodies B-Raf inhibitor RAF265 [5-(2-(5-(trifluromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)-N-(4-trifluoromethyl)phenyl-1-methyl-1H-benzp{D, }imidazol-2- amine] was kindly provided by Novartis Pharma AG and dissolved in solvent ethanol:propylene glycol:2.5% tween-80 (percentage 6:23:71) for oral delivery to mice by gavage. Antibodies to phospho-ERK1/2 Thr202/Tyr204(4370), phosphoMEK1/2(2338 and 9121)), phospho-cyclin D1(3300), cyclin D1 (2978), PLK1 (4513) BIM (2933), BAX (2772), BCL2 (2876) were from Cell Signaling Technology. Additional antibodies for phospho-ERK1,2 detection for western blot were from Promega (V803A), and Santa Cruz (E-Y, SC7383). Total ERK antibody for western blot analysis was K-23 from Santa Cruz (SC-94). Ki67 antibody (ab833) was from ABCAM, Mcl1 antibody (559027) was from BD Biosciences, Factor VIII antibody was from Dako (A082), CD31 antibody was from Dianova, (DIA310), and Cot antibody was from Santa Cruz Biotechnology (sc-373677). For the cyclin D1 second antibody staining was with an Alexa Fluor 568 donkey anti-rabbit IgG (Invitrogen, A10042) (1:200 dilution). The pMEK1 fluorescence was developed using the Alexa Fluor 488 chicken anti-rabbit IgG second antibody (1:200 dilution).TUNEL staining kits were from Promega (G2350). Mouse Implant Studies: Biopsy tissues were delivered to research laboratory in ice-cold Dulbecco's Modified Eagle Medium (DMEM) buffer solution. As the tissue mass available from each biopsy was limited, we first passaged the biopsy tissue in Balb/c nu/Foxn1 athymic nude mice (6-8 weeks of age and weighing 22-25g, purchased from Harlan Sprague Dawley, USA) to increase the volume of tumor for further implantation.
    [Show full text]
  • STRIPAK Complexes in Cell Signaling and Cancer
    Oncogene (2016), 1–9 © 2016 Macmillan Publishers Limited All rights reserved 0950-9232/16 www.nature.com/onc REVIEW STRIPAK complexes in cell signaling and cancer Z Shi1,2, S Jiao1 and Z Zhou1,3 Striatin-interacting phosphatase and kinase (STRIPAK) complexes are striatin-centered multicomponent supramolecular structures containing both kinases and phosphatases. STRIPAK complexes are evolutionarily conserved and have critical roles in protein (de) phosphorylation. Recent studies indicate that STRIPAK complexes are emerging mediators and regulators of multiple vital signaling pathways including Hippo, MAPK (mitogen-activated protein kinase), nuclear receptor and cytoskeleton remodeling. Different types of STRIPAK complexes are extensively involved in a variety of fundamental biological processes ranging from cell growth, differentiation, proliferation and apoptosis to metabolism, immune regulation and tumorigenesis. Growing evidence correlates dysregulation of STRIPAK complexes with human diseases including cancer. In this review, we summarize the current understanding of the assembly and functions of STRIPAK complexes, with a special focus on cell signaling and cancer. Oncogene advance online publication, 15 February 2016; doi:10.1038/onc.2016.9 INTRODUCTION in the central nervous system and STRN4 is mostly abundant in Recent proteomic studies identified a group of novel multi- the brain and lung, whereas STRN3 is ubiquitously expressed in 5–9 component complexes named striatin (STRN)-interacting phos- almost all tissues. STRNs share a
    [Show full text]
  • Molecular Signatures Differentiate Immune States in Type 1 Diabetes Families
    Page 1 of 65 Diabetes Molecular signatures differentiate immune states in Type 1 diabetes families Yi-Guang Chen1, Susanne M. Cabrera1, Shuang Jia1, Mary L. Kaldunski1, Joanna Kramer1, Sami Cheong2, Rhonda Geoffrey1, Mark F. Roethle1, Jeffrey E. Woodliff3, Carla J. Greenbaum4, Xujing Wang5, and Martin J. Hessner1 1The Max McGee National Research Center for Juvenile Diabetes, Children's Research Institute of Children's Hospital of Wisconsin, and Department of Pediatrics at the Medical College of Wisconsin Milwaukee, WI 53226, USA. 2The Department of Mathematical Sciences, University of Wisconsin-Milwaukee, Milwaukee, WI 53211, USA. 3Flow Cytometry & Cell Separation Facility, Bindley Bioscience Center, Purdue University, West Lafayette, IN 47907, USA. 4Diabetes Research Program, Benaroya Research Institute, Seattle, WA, 98101, USA. 5Systems Biology Center, the National Heart, Lung, and Blood Institute, the National Institutes of Health, Bethesda, MD 20824, USA. Corresponding author: Martin J. Hessner, Ph.D., The Department of Pediatrics, The Medical College of Wisconsin, Milwaukee, WI 53226, USA Tel: 011-1-414-955-4496; Fax: 011-1-414-955-6663; E-mail: [email protected]. Running title: Innate Inflammation in T1D Families Word count: 3999 Number of Tables: 1 Number of Figures: 7 1 For Peer Review Only Diabetes Publish Ahead of Print, published online April 23, 2014 Diabetes Page 2 of 65 ABSTRACT Mechanisms associated with Type 1 diabetes (T1D) development remain incompletely defined. Employing a sensitive array-based bioassay where patient plasma is used to induce transcriptional responses in healthy leukocytes, we previously reported disease-specific, partially IL-1 dependent, signatures associated with pre and recent onset (RO) T1D relative to unrelated healthy controls (uHC).
    [Show full text]
  • Oncogenic Tyrosine Kinase of Malignant Hemopathy Targets the Centrosome
    Research Article Oncogenic Tyrosine Kinase of Malignant Hemopathy Targets the Centrosome Be´ne´dicte Delaval,1 Se´bastien Le´tard,2 He´le`ne Lelie`vre,1 Ve´ronique Chevrier,3 Laurent Daviet,4 Patrice Dubreuil,2 and Daniel Birnbaum1 Laboratories of 1Molecular Oncology and 2Molecular Hematopoiesis, Marseille Cancer Institute, UMR599 Inserm and Institut Paoli-Calmettes, Marseilles, France; 3U366 Inserm, Grenoble; and 4Hybrigenics S.A., Paris, France Abstract fusions. The receptor transmembrane region is not conserved in the fusion. X-FGFR1 proteins promote cell survival through Myeloproliferative disorders (MPD) are malignant diseases of g hematopoietic progenitor cells. Many MPDs result from a signaling pathways involving, among others, phospholipase C g chromosomal translocation that creates a fusion gene encod- (PLC ), phosphoinositol-3 kinase (PI3K), AKT and STAT proteins ing a chimeric kinase. The fibroblast growth factor receptor 1 (9–12). The disease has been reproduced in mouse bone marrow (FGFR1)-MPD is characterized by the fusion of the FGFR1 transplantation models (13–15). The effects of X-FGFR1 proteins kinase with various partners, including FOP. We show here can be abrogated by treatment with an inhibitor of the FGFR1 that both normal FOP and FOP-FGFR1 fusion kinase localize kinase (7, 14, 15). to the centrosome. The fusion kinase encounters substrates at The subcellular localization of X-FGFR1 proteins has been the centrosome where it induces strong phosphorylation on studied, however, often only coarsely and in transfected cells with tyrosine residues. Treatment with FGFR1 kinase inhibitor high levels of expression; fusion proteins are found predominantly in the cytoplasm. Normal partners have been found at various SU5402 abolishes FOP-FGFR1-induced centrosomal phosphor- ylation and suppresses the proliferative and survival potentials subcellular localizations.
    [Show full text]
  • Downregulation of Carnitine Acyl-Carnitine Translocase by Mirnas
    Page 1 of 288 Diabetes 1 Downregulation of Carnitine acyl-carnitine translocase by miRNAs 132 and 212 amplifies glucose-stimulated insulin secretion Mufaddal S. Soni1, Mary E. Rabaglia1, Sushant Bhatnagar1, Jin Shang2, Olga Ilkayeva3, Randall Mynatt4, Yun-Ping Zhou2, Eric E. Schadt6, Nancy A.Thornberry2, Deborah M. Muoio5, Mark P. Keller1 and Alan D. Attie1 From the 1Department of Biochemistry, University of Wisconsin, Madison, Wisconsin; 2Department of Metabolic Disorders-Diabetes, Merck Research Laboratories, Rahway, New Jersey; 3Sarah W. Stedman Nutrition and Metabolism Center, Duke Institute of Molecular Physiology, 5Departments of Medicine and Pharmacology and Cancer Biology, Durham, North Carolina. 4Pennington Biomedical Research Center, Louisiana State University system, Baton Rouge, Louisiana; 6Institute for Genomics and Multiscale Biology, Mount Sinai School of Medicine, New York, New York. Corresponding author Alan D. Attie, 543A Biochemistry Addition, 433 Babcock Drive, Department of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin, (608) 262-1372 (Ph), (608) 263-9608 (fax), [email protected]. Running Title: Fatty acyl-carnitines enhance insulin secretion Abstract word count: 163 Main text Word count: 3960 Number of tables: 0 Number of figures: 5 Diabetes Publish Ahead of Print, published online June 26, 2014 Diabetes Page 2 of 288 2 ABSTRACT We previously demonstrated that micro-RNAs 132 and 212 are differentially upregulated in response to obesity in two mouse strains that differ in their susceptibility to obesity-induced diabetes. Here we show the overexpression of micro-RNAs 132 and 212 enhances insulin secretion (IS) in response to glucose and other secretagogues including non-fuel stimuli. We determined that carnitine acyl-carnitine translocase (CACT, Slc25a20) is a direct target of these miRNAs.
    [Show full text]
  • Research Article Complex and Multidimensional Lipid Raft Alterations in a Murine Model of Alzheimer’S Disease
    SAGE-Hindawi Access to Research International Journal of Alzheimer’s Disease Volume 2010, Article ID 604792, 56 pages doi:10.4061/2010/604792 Research Article Complex and Multidimensional Lipid Raft Alterations in a Murine Model of Alzheimer’s Disease Wayne Chadwick, 1 Randall Brenneman,1, 2 Bronwen Martin,3 and Stuart Maudsley1 1 Receptor Pharmacology Unit, National Institute on Aging, National Institutes of Health, 251 Bayview Boulevard, Suite 100, Baltimore, MD 21224, USA 2 Miller School of Medicine, University of Miami, Miami, FL 33124, USA 3 Metabolism Unit, National Institute on Aging, National Institutes of Health, 251 Bayview Boulevard, Suite 100, Baltimore, MD 21224, USA Correspondence should be addressed to Stuart Maudsley, [email protected] Received 17 May 2010; Accepted 27 July 2010 Academic Editor: Gemma Casadesus Copyright © 2010 Wayne Chadwick et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Various animal models of Alzheimer’s disease (AD) have been created to assist our appreciation of AD pathophysiology, as well as aid development of novel therapeutic strategies. Despite the discovery of mutated proteins that predict the development of AD, there are likely to be many other proteins also involved in this disorder. Complex physiological processes are mediated by coherent interactions of clusters of functionally related proteins. Synaptic dysfunction is one of the hallmarks of AD. Synaptic proteins are organized into multiprotein complexes in high-density membrane structures, known as lipid rafts. These microdomains enable coherent clustering of synergistic signaling proteins.
    [Show full text]
  • STRIPAK, a Highly Conserved Signaling Complex, Controls Multiple
    Biol. Chem. 2019; 400(8): 1005–1022 Review Ulrich Kück*, Daria Radchenko and Ines Teichert STRIPAK, a highly conserved signaling complex, controls multiple eukaryotic cellular and developmental processes and is linked with human diseases https://doi.org/10.1515/hsz-2019-0173 networks are now known to underlie the transmission and Received February 27, 2019; accepted March 28, 2019; previously modulation of such signals. These networks, controlled published online May 1, 2019 by diverse regulators at different cellular levels, are highly conserved across eukaryotic organisms. Abstract: The striatin-interacting phosphatases and Among the signaling components that have received kinases (STRIPAK) complex is evolutionary highly con- increased attention in the last decade is the STRIPAK served and has been structurally and functionally complex, which was initially identified in mammals by described in diverse lower and higher eukaryotes. In recent mass spectrometry (MS) analysis (Goudreault et al., 2009). years, this complex has been biochemically characterized Here we will provide a summary of the key studies leading better and further analyses in different model systems have to the discovery of striatin, the major regulatory phos- shown that it is also involved in numerous cellular and phatase subunit of the STRIPAK complex. Further, the developmental processes in eukaryotic organisms. Fur- components and architecture as well as the assembly and ther recent results have shown that the STRIPAK complex structural insights of the STRIPAK complex will be com- functions as a macromolecular assembly communicating prehensively reviewed. Another focus will be the control through physical interaction with other conserved signal- of developmental processes as a result of bi-directional ing protein complexes to constitute larger dynamic protein interaction of STRIPAK with other components involved networks.
    [Show full text]
  • Autocrine IFN Signaling Inducing Profibrotic Fibroblast Responses By
    Downloaded from http://www.jimmunol.org/ by guest on September 23, 2021 Inducing is online at: average * The Journal of Immunology , 11 of which you can access for free at: 2013; 191:2956-2966; Prepublished online 16 from submission to initial decision 4 weeks from acceptance to publication August 2013; doi: 10.4049/jimmunol.1300376 http://www.jimmunol.org/content/191/6/2956 A Synthetic TLR3 Ligand Mitigates Profibrotic Fibroblast Responses by Autocrine IFN Signaling Feng Fang, Kohtaro Ooka, Xiaoyong Sun, Ruchi Shah, Swati Bhattacharyya, Jun Wei and John Varga J Immunol cites 49 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2013/08/20/jimmunol.130037 6.DC1 This article http://www.jimmunol.org/content/191/6/2956.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 23, 2021. The Journal of Immunology A Synthetic TLR3 Ligand Mitigates Profibrotic Fibroblast Responses by Inducing Autocrine IFN Signaling Feng Fang,* Kohtaro Ooka,* Xiaoyong Sun,† Ruchi Shah,* Swati Bhattacharyya,* Jun Wei,* and John Varga* Activation of TLR3 by exogenous microbial ligands or endogenous injury-associated ligands leads to production of type I IFN.
    [Show full text]
  • A Systems Immunology Approach Identifies the Collective Impact of Five Mirs in Th2 Inflammation Supplementary Information
    A systems immunology approach identifies the collective impact of five miRs in Th2 inflammation Supplementary information Ayşe Kılıç, Marc Santolini, Taiji Nakano, Matthias Schiller, Mizue Teranishi,Pascal Gellert, Yuliya Ponomareva, Thomas Braun, Shizuka Uchida, Scott T. Weiss, Amitabh Sharma and Harald Renz Corresponding Author: Harald Renz, MD Institute of Laboratory Medicine Philipps University Marburg 35043 Marburg, Germany Phone +49 6421 586 6235 [email protected] 1 Kılıç A et. al. 2018 A B C D PBS OVA chronic PAS PAS (cm H2O*s/ml (cm Raw Sirius Red Sirius Supplementary figure 1: Characteristic phenotype of the acute and chronic allergic airway inflammatory response in the OVA-induced mouse model. (a) Total and differential cell counts determined in BAL and cytospins show a dominant influx of eosinophils. (b) Serum titers of OVA-specific immunoglobulins are elevated. (c) Representative measurement of airway reactivity to increasing methacholine (Mch) responsiveness measured by head-out body plethysmography. (d) Representative lung section staining depicting airway inflammation and mucus production (PAS, original magnification x 10) and airway remodeling (SiriusRed; original magnification x 20). Data are presented as mean ± SEM and are representative for at least 3 independent experiments with n=8-10 animals per group. Statistical analyses have been performed with one-way ANOVA and Tukey’s post-test and show *p<0.05, **p<0.01 and ***p<0.001. 2 Kılıç A et. al. 2018 lymphocytes A lung activated CD4+-cells CD4+-T-cell-subpopulations SSC FSC ST2 live CD69 CD4 CXCR3 B spleen Naive CD4+- T cells DAPI FSC single cells SSC CD62L CD4 CD44 FSC FSC-W Supplementary figure 2.
    [Show full text]
  • A Meta-Analysis of the Effects of High-LET Ionizing Radiations in Human Gene Expression
    Supplementary Materials A Meta-Analysis of the Effects of High-LET Ionizing Radiations in Human Gene Expression Table S1. Statistically significant DEGs (Adj. p-value < 0.01) derived from meta-analysis for samples irradiated with high doses of HZE particles, collected 6-24 h post-IR not common with any other meta- analysis group. This meta-analysis group consists of 3 DEG lists obtained from DGEA, using a total of 11 control and 11 irradiated samples [Data Series: E-MTAB-5761 and E-MTAB-5754]. Ensembl ID Gene Symbol Gene Description Up-Regulated Genes ↑ (2425) ENSG00000000938 FGR FGR proto-oncogene, Src family tyrosine kinase ENSG00000001036 FUCA2 alpha-L-fucosidase 2 ENSG00000001084 GCLC glutamate-cysteine ligase catalytic subunit ENSG00000001631 KRIT1 KRIT1 ankyrin repeat containing ENSG00000002079 MYH16 myosin heavy chain 16 pseudogene ENSG00000002587 HS3ST1 heparan sulfate-glucosamine 3-sulfotransferase 1 ENSG00000003056 M6PR mannose-6-phosphate receptor, cation dependent ENSG00000004059 ARF5 ADP ribosylation factor 5 ENSG00000004777 ARHGAP33 Rho GTPase activating protein 33 ENSG00000004799 PDK4 pyruvate dehydrogenase kinase 4 ENSG00000004848 ARX aristaless related homeobox ENSG00000005022 SLC25A5 solute carrier family 25 member 5 ENSG00000005108 THSD7A thrombospondin type 1 domain containing 7A ENSG00000005194 CIAPIN1 cytokine induced apoptosis inhibitor 1 ENSG00000005381 MPO myeloperoxidase ENSG00000005486 RHBDD2 rhomboid domain containing 2 ENSG00000005884 ITGA3 integrin subunit alpha 3 ENSG00000006016 CRLF1 cytokine receptor like
    [Show full text]